Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update
09. November 2017 07:00 ET
|
Arcturus Therapeutics
TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD) today announced financial results for the three and nine months ended September 30, 2017, and provided a corporate...
Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update
11. August 2017 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three and six months ended June 30, 2017, and provided a corporate update. ...
Alcobra Updates on its Review of Strategic Alternatives
23. Juni 2017 07:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, June 23, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical...
Alcobra Announces Cooperation Agreement with Brosh Group and Board Additions
12. Juni 2017 08:36 ET
|
Alcobra Ltd.
Company Adds Two Directors to the Board Company to Continue Strategic Alternatives Process to Maximize Value for All Shareholders TEL AVIV, Israel, June 12, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd....
Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update
30. Mai 2017 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three months ended March 31, 2017, and provided a corporate update. First...
Alcobra Announces Leadership Update
15. Mai 2017 08:00 ET
|
Alcobra Ltd.
Dr. Yaron Daniely to Step Down as Chief Executive Officer, Effective May 31, 2017 David Baker Named Interim Chief Executive Officer Dr. Daniely to Remain on Board of Directors and be Appointed...
Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group
05. Mai 2017 12:42 ET
|
Alcobra Ltd.
TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical...
Alcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders
24. April 2017 06:00 ET
|
Alcobra Ltd.
The Board Will Defend Shareholders from Opportunistic Takeover of the Company Believes Brosh Capital's Request Does Not Comply With Alcobra's Articles of Association TEL AVIV, Israel, April 24,...
Alcobra Provides Update on Request for Extraordinary General Meeting
05. April 2017 08:00 ET
|
Alcobra Ltd.
Brosh Capital’s Request Does Not Comply With Alcobra’s Articles of Association Company Addresses Brosh Capital’s Misinformed Views TEL AVIV, Israel, April 05, 2017 (GLOBE NEWSWIRE) --...
Alcobra Ltd. to Participate in Upcoming Healthcare Conferences
07. März 2017 08:00 ET
|
Alcobra Ltd.
TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system...